EMERGENT BIOSOLUTIONS INC. Operating Lease, Lease Income
EMERGENT BIOSOLUTIONS INC. (EBS) reported Operating Lease, Lease Income of $62.10 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseLeaseIncome · last filed 2022-02-25
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for the quarter ending 2021-06-30 was $16.90M.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for the quarter ending 2021-03-31 was $18.70M.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for the quarter ending 2020-12-31 was $12.40M.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for the quarter ending 2020-09-30 was $18.10M.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for fiscal 2021 was $62.10M, a 103.61% increase from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for fiscal 2020 was $30.50M.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for fiscal 2019 was $0.00.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income for fiscal 2018 was $0.00.
| Period end | Operating Lease, Lease Income 3 month | Operating Lease, Lease Income 6 month | Operating Lease, Lease Income 9 month | Operating Lease, Lease Income 12 month |
|---|---|---|---|---|
| 2021-12-31 | $62.10M 10-K · filed 2022-02-25 | |||
| 2021-06-30 | $16.90M 10-Q · filed 2021-07-30 | $35.60M 10-Q · filed 2021-07-30 | $48.00M derived: sum of 3 quarters · filed 2021-07-30 | $66.10M derived: sum of 4 quarters · filed 2021-07-30 |
| 2021-03-31 | $18.70M 10-Q · filed 2021-04-30 | $31.10M derived: sum of 2 quarters · filed 2021-04-30 | $49.20M derived: sum of 3 quarters · filed 2021-04-30 | $49.20M derived: sum of 4 quarters · filed 2021-07-30 |
| 2020-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $30.50M derived: sum of 2 quarters · filed 2021-02-19 | $30.50M derived: sum of 3 quarters · filed 2021-07-30 | $30.50M 10-K · filed 2021-02-19 |
| 2020-09-30 | $18.10M 10-Q · filed 2020-11-06 | $18.10M derived: sum of 2 quarters · filed 2021-07-30 | $18.10M 10-Q · filed 2020-11-06 | $18.10M derived: sum of 4 quarters · filed 2021-07-30 |
| 2020-06-30 | $0.00 10-Q · filed 2021-07-30 | $0.00 10-Q · filed 2021-07-30 | $0.00 derived: sum of 3 quarters · filed 2021-07-30 | $0.00 derived: sum of 4 quarters · filed 2021-07-30 |
| 2020-03-31 | $0.00 10-Q · filed 2021-04-30 | $0.00 derived: sum of 2 quarters · filed 2021-04-30 | $0.00 derived: sum of 3 quarters · filed 2021-04-30 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $0.00 derived: sum of 2 quarters · filed 2021-02-19 | $0.00 10-K · filed 2021-02-19 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |